Drug intelligence / Profile preview

[18F]DMPY2

Development stage: Unknown
Lead developer: CNcure
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]DMPY2 is a fluorine-18 labeled positron emission tomography (PET) imaging radiotracer developed by CNcure for the detection and staging of malignant melanoma. The tracer is designed to specifically bind to melanin, a pigment produced by melanocytes that is often present in high concentrations in melanoma cells. By targeting melanin, [18F]DMPY2 aims to provide high-contrast imaging of primary and metastatic melanoma lesions, potentially offering superior sensitivity compared to standard tracers like [18F]FDG, which can be limited by high background uptake in certain tissues. The agent is currently in Phase 1 clinical development.

Other names: 18F-DMPY2

Beyond the preview

Go deeper on [18F]DMPY2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]DMPY2.

Explore the full profile